Egetis Therapeutics ABPDPHF 24 Current Ratio is 0.69 as of Mar. 2026, which is 87% below its 10-year median of 5.37. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Egetis Therapeutics AB ranks worse than 88.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Egetis Therapeutics AB's current ratio for the quarter that ended in Mar. 2026 was 0.69.
Egetis Therapeutics AB has a current ratio of 0.69. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Egetis Therapeutics AB has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Egetis Therapeutics AB's Current Ratio or its related term are showing as below:
PDPHF'
s Current Ratio Range Over the Past 10 Years
Min: 0.69 Med: 5.37 Max: 65.88
Current: 0.69
During the past 13 years, Egetis Therapeutics AB's highest Current Ratio was 65.88. The lowest was 0.69. And the median was 5.37.
PDPHF's Current Ratio is ranked worse than 88.64% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs PDPHF: 0.69
Egetis Therapeutics AB (OTCPK:PDPHF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Egetis Therapeutics AB Current Ratio Related Terms
Egetis Therapeutics AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDPHF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (PDPHF) has a Current Ratio of 0.69 as of Mar. 2026. This is 87% below median its historical median of 5.37. Over the past decade, Egetis Therapeutics AB's Current Ratio has ranged from 0.69 to 65.88. According to the industry distribution chart, Egetis Therapeutics AB ranks #1256 out of 1417 companies in the Biotechnology industry, placing it in the top 88.6%.
Is Egetis Therapeutics AB's Current Ratio too high?
Egetis Therapeutics AB's current Current Ratio of 0.69 is 87% below median its 10-year median of 5.37. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 65.88. The Biotechnology industry median Current Ratio is 3.89. Egetis Therapeutics AB's value of 0.69 is 82.3% below this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #1256 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #1256 out of 1417 companies for Current Ratio. This places Egetis Therapeutics AB in the lower half of its industry. The industry median Current Ratio is 3.89. Egetis Therapeutics AB's value of 0.69 is 82.3% below this benchmark. Historically, Egetis Therapeutics AB's own Current Ratio has ranged from 0.69 to 65.88 over the past decade. While the company's 10-year median is 5.37 vs. the industry median of 3.89, Egetis Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current Current Ratio of 0.69 is 82.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current Current Ratio is 0.69, which is 87% below median its own 10-year median of 5.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Current Ratio is 0.69, which is 87% below median its 10-year median of 5.37 and 82.3% below the Biotechnology industry median of 3.89. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Current Ratio is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued.
The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64.
GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.
Key valuation signals for PDPHF:
Current Ratio: 0.69 (87% below median its 10-year median of 5.37)
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
Industry Position: 82.3% below the Biotechnology median (#1256 of 1417)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score
Get the complete analysis for PDPHF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
